Literature DB >> 8031067

In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.

K E Aldridge1, N Morice, D D Schiro.   

Abstract

We tested 441 clinical strains of anaerobes by using a broth microdilution method to determine the in vitro activity of biapenem for comparison with those of other agents. Biapenem had activity comparable to those of imipenem and meropenem against all groups of anaerobes with MICs for 90% of the strains tested of 0.06 to 2 micrograms/ml. Against the Bacteroides fragilis group, biapenem was more active than ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin, cefoxitin, cefotaxime, and ceftriaxone. Biapenem was also active against all of the B. capillosus, Prevotella, Clostridium, and Eubacterium strains and anaerobic cocci tested. Against all of the anaerobes tested, biapenem was 32- and 4-fold more active than clindamycin and metronidazole, respectively. These data indicate broad-spectrum activity by biapenem against anaerobes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031067      PMCID: PMC284564          DOI: 10.1128/AAC.38.4.889

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro activity of L-627 against anaerobic bacteria.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

2.  In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.

Authors:  G J Malanoski; L Collins; C Wennersten; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

3.  Properties of a new penicillinase type produced by Bacteroides fragilis.

Authors:  K Sato; Y Matsuura; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

4.  Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.

Authors:  H S Sader; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

Review 5.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

6.  Characterization of three different beta-lactamases from the Bacteroides fragilis group.

Authors:  B Olsson-Liljequist; K Dornbusch; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

7.  Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex.

Authors:  M Hikida; K Kawashima; M Yoshida; S Mitsuhashi
Journal:  J Antimicrob Chemother       Date:  1992-08       Impact factor: 5.790

8.  Transfer of beta-lactamase-associated cefoxitin resistance in Bacteroides fragilis.

Authors:  G J Cuchural; F P Tally; J R Storey; M H Malamy
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

9.  Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.

Authors:  H Kropp; J G Sundelof; R Hajdu; F M Kahan
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

10.  In vitro activity of L-627, a new carbapenem.

Authors:  C R Catchpole; R Wise; D Thornber; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

View more
  7 in total

1.  Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.

Authors:  Sangeetha Rajenderan; Veeraraghavan Balaji; Shalini Anandan; Rani Diana Sahni; Giannoula S Tansarli; Matthew E Falagas
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

Review 2.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 3.  Biapenem.

Authors:  Caroline M Perry; Tim Ibbotson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.

Authors:  Ellie J C Goldstein; Diane M Citron; Kerin L Tyrrell; C Vreni Merriam
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

Review 5.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

6.  Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa.

Authors:  G Meletis; M Exindari; N Vavatsi; D Sofianou; E Diza
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

7.  Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial.

Authors:  Xiaohui Wang; Xiaoke Zhang; Zhiyong Zong; Rujia Yu; Xiaoju Lv; Jianbao Xin; Chaohui Tong; Qinglin Hao; Zhiqiang Qin; Ying Xiong; Hong Liu; Guohua Ding; Chengping Hu
Journal:  Indian J Med Res       Date:  2013-12       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.